Last reviewed · How we verify
NCT03698162
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
NA trial testing Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Brain Metastases in 15 participants. Terminated before completion.
22 November 2023
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 15 |
| Start date | 13 April 2021 |
| Primary completion | 22 November 2023 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Bevacizumab Injection — full drug profile →
Conditions studied
- Brain Metastases — all drugs for Brain Metastases →
- Glioma of Brain — all drugs for Glioma of Brain →
- Brain Tumor — all drugs for Brain Tumor →
- Metastatic Melanoma — all drugs for Metastatic Melanoma →
Sponsor
University of Southern California
Who can join
21 and older, any sex, with Brain Metastases or Glioma of Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high grade glioma that has come back or melanoma that has spread to the brain. The specially-tailored acquisition and reconstruction (STAR) DCE MRI could provide improved assessment of brain tumor status and response to therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03698162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Trials testing the same drug.
- NCT05250895 — BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cance · EARLY_PHASE1 · completed
- NCT03091803 — QSM and Regional DCE MRI Permeability Using GOCART Technique · withdrawn
- NCT03145077 — Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Can · NA · recruiting
- NCT02744053 — DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer · EARLY_PHASE1 · active not recruiting
- NCT02526511 — Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors · NA · unknown
Other recruiting trials for Brain Metastases
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
- NCT07227610 — Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · Phase 2 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03698162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03698162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing